Otsuka Pharmaceutical Co., Ltd. has entered an agreement to acquire all outstanding shares Astex Pharmaceuticals, Inc. for approximately $886 million in cash. The transaction is expected to close early in 4Q13, subject to customary closing conditions. Astex is dedicated to the discovery and development of novel small molecule therapeutics with a particular focus on oncology. Its myelodysplastic syndromes (MDS) franchise includes DACOGEN (decitabine) for Injection, which also gained approval in ...